The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.46BCNY
668.24M · vs all stocks (USD)
Updated Oct 23, 2026
Revenue (TTM)
648.86MCNY
97.26M · vs all stocks (USD)
Updated Oct 23, 2026
Profit Margin
-5.21%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Beta
-0.1660x
vs all stocks
Updated Oct 23, 2026
52-Week Change
70.47%
vs all stocks
Updated Oct 23, 2026
Market Capitalization
4.46BCNY
668.24M · vs all stocks (USD)
Updated Oct 23, 2026
Enterprise Value
4.29BCNY
642.47M · vs all stocks (USD)
Updated Oct 23, 2026
Price to Sales (TTM)
6.77x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Price to Book (MRQ)
4.23x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Enterprise to Revenue
6.61x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Enterprise to EBITDA
-127.32x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Gross Margin
17.21%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 14.71%.Updated Oct 23, 2026
Profit Margin
-5.21%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Operating Margin
0.40%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Return on Assets (TTM)
-1.65%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Return on Equity (TTM)
-3.13%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Revenue (TTM)
648.86MCNY
97.26M · vs all stocks (USD)
Updated Oct 23, 2026
Revenue per Share (TTM)
1.53CNYUpdated Oct 23, 2026
Quarterly Revenue Growth
-3.90%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Gross Profit (TTM)
95.47MCNY
14.31M · vs all stocks (USD)
Updated Oct 23, 2026
EBITDA (TTM)
-33.66MCNY
-5.05M · vs all stocks (USD)
Updated Oct 23, 2026
Net Income (TTM)
-33.80MCNY
-5.07M · vs all stocks (USD)
Updated Oct 23, 2026
Quarterly Earnings Growth (YoY)
4.93%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Operating Cash Flow (TTM)
-54.82MCNY
-8.22M · vs all stocks (USD)
Updated Oct 23, 2026
Levered Free Cash Flow (TTM)
-33.42MCNY
-5.01M · vs all stocks (USD)
Updated Oct 23, 2026
5-Year Average Dividend Yield
1.19%
vs all stocks
Updated Oct 23, 2026
Payout Ratio
200.00%
vs Diagnostics & Research peers
Updated Oct 23, 2026
Minority Interest (Equity)
1.74MCNYFY2025 · Dec 31, 2025
Revenue
677.79MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
577.78MCNYFY2025 · Dec 31, 2025
Gross Profit
100.01MCNYFY2025 · Dec 31, 2025
Operating Income
-23.53MCNY
-3.53M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-40.12MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-6.43MCNYFY2025 · Dec 31, 2025
Net Income
-33.69MCNYFY2025 · Dec 31, 2025
EBIT
-37.80MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-10.15MCNYFY2025 · Dec 31, 2025
Research & Development
3.81MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
39.87MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
2.51MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
5.66MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.32MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.0800CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.0800CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
420.54MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
420.54MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-33.69MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
44.76KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-29.60MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-43.65MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
86.40MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-33.69MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
17.29MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
4.20MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-17.41MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-14.04MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-286.63MCNYFY2025 · Dec 31, 2025
Sale of Investments
158.26MCNYFY2025 · Dec 31, 2025
Other Investing Activity
1.26MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-141.16MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
126.97MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-114.99MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-52.66MCNYFY2025 · Dec 31, 2025
Other Financing Charges
6.39MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-34.28MCNYFY2025 · Dec 31, 2025
Shares Outstanding
398.05MSharesUpdated Oct 23, 2026
Float Shares
172.48MSharesUpdated Oct 23, 2026
% Held by Insiders
54.20%
vs all stocks
Updated Oct 23, 2026
% Held by Institutions
1.09%
vs all stocks
Updated Oct 23, 2026
Total Cash (MRQ)
137.90MCNY
20.67M · vs all stocks (USD)
Updated Oct 23, 2026
Total Cash per Share (MRQ)
0.3460CNYUpdated Oct 23, 2026
Total Debt (MRQ)
31.41MCNY
4.71M · vs all stocks (USD)
Updated Oct 23, 2026
Total Debt to Equity (MRQ)
0.0302x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Current Ratio (MRQ)
2.96x
vs Diagnostics & Research peers
Updated Oct 23, 2026
Book Value per Share (MRQ)
2.61CNYUpdated Oct 23, 2026
Total Assets
1.43BCNY
214.12M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.12BCNYFY2025 · Dec 31, 2025
Total Liabilities
368.90MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
304.24MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
2.02MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
366.88MCNYFY2025 · Dec 31, 2025
Cash
96.40MCNYFY2025 · Dec 31, 2025
Cash Equivalents
10.07MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
106.47MCNYFY2025 · Dec 31, 2025
Accounts Receivable
690.03MCNYFY2025 · Dec 31, 2025
Inventory
172.64MCNYFY2025 · Dec 31, 2025
Accounts Payable
266.40MCNYFY2025 · Dec 31, 2025
Short-term Debt
59.26MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
361.94KCNYFY2025 · Dec 31, 2025
Long-term Debt
2.02MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
398.05MCNYFY2025 · Dec 31, 2025
Retained Earnings
43.93MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.06BCNY
158.83M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
6.52CNYUpdated Oct 23, 2026
52-Week High
31.22CNYUpdated Oct 23, 2026
52-Week Change
70.47%
vs all stocks
Updated Oct 23, 2026
Beta
-0.1660x
vs all stocks
Updated Oct 23, 2026
50-Day MA
12.93CNYUpdated Oct 23, 2026
200-Day MA
14.30CNYUpdated Oct 23, 2026
Avg 10-Day Volume
27.13MSharesUpdated Oct 23, 2026
Avg 30-Day Volume
38.97MSharesUpdated Oct 23, 2026
Diluted EPS (TTM)
-0.0800CNYUpdated Oct 23, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 17.2%, lower than 95% of its Diagnostics & Research peers (median 56.7%)Significant